Overview

Regorafenib in Relapsed Glioblastoma

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the role of Regorafenib in prolonging the overall survival of glioblastoma multiforme patients who progressed after surgery and Stupp regimen with or without bevacizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Istituto Oncologico Veneto IRCCS

Collaborator:

BAYER S.p.A. - Italia

Treatments:

Lomustine